申请人:Astrazeneca AB
公开号:US08329729B2
公开(公告)日:2012-12-11
The invention provides named compounds of formula (I), wherein R4 is a N-substituted quinuclidine (I) pharmaceutical compositions containing them and a process for preparing the pharmaceutical compositions. Their use in therapy for the treatment of conditions mediated by M3 muscarinic receptors, such as chronic obstructive pulmonary disease is also disclosed.
该发明提供了式(I)的命名化合物,其中R4是一种N-取代的喹诺啉,还提供了含有这些化合物的制药组合物以及制备制药组合物的过程。还披露了它们在治疗由M3胆碱能受体介导的疾病,如慢性阻塞性肺疾病的用途。